An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis

Tinea Corporis Clinical Trial

Official title:
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis

Status Completed

Clinical Trial Summary

This is an open label, multi-center, multi-application pharmacokinetic study in pediatric subjects with tinea corporis.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02466867
Study type	Interventional
Source	Merz Pharmaceuticals, LLC
Contact
Status	Completed
Phase	Phase 4
Start date	January 2014
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05881980` - Efficacy and Safety of Terbinafine and Itraconazole	Phase 2/Phase 3
Completed	`NCT01349998` - Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis	Phase 3
Completed	`NCT02767947` - Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis	Phase 4
Completed	`NCT02227290` - Pediatric Subjects With Tinea Corporis	Phase 4
Not yet recruiting	`NCT01105013` - Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections	Phase 3